Navigation Links
AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
Date:6/29/2009

    GAI-122, an investigational injectable nanoemulsion formulated with
    AlphaRx's proprietary drug delivery technology, providing significant
    neuro-protection in multiple in vitro and in vivo studies which suggest
    that this injectable nanoemulsion formulation has the potential to
    prevent postoperative delirium

MARKHAM, ON, June 29 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited today reported positive pre-clinical results on GAI-122 injectable nanoemulsion in multiple in vitro and in vivo studies of memory impairment after prolonged anesthesia.

Delirium is a common mental disorder with serious adverse outcomes in post-operative hospitalized patients. It is associated with an increase in mortality, physical morbidity, length of hospital stay, institutionalization of patients and increased cost to healthcare providers. Ten to thirty percent of admissions of patients over 65 years of age to a general hospitals develop delirium after surgery and the incidence rate can be as high as 50% in patients who undergone high risk and lengthy procedures such as hip replacement and cardiac surgeries. There is no preventive therapy currently available for post-operative delirium.

"There are over 10,000,000 inpatient surgeries performed annually in the U.S. on patients over the age of 65, and up to 40% of these seniors will develop post-operative delirium. There is an urgent need to develop a medicine, such as GAI-122 injectable nanoemulsion, for the preventive of this debilitating post-operative condition," said Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx.

In rat model studies, injected GAI-122 ameliorates learning and memory disturbances produced by cerebral embolization, cerebral ischemia or lesions in the basal forebrain, the area of origin of the acetylcholine neuron system projecting into the cerebral cortex, hippocampus and amygdala. In clinical tests, an oral form of GAI-122 has been shown to be effective in psychological deficits such as a decline in memory retention and disorientation.

In October 2008, AlphaRx licensed GAI-122 to Gaia BioPharma. Under the terms of the amended agreement, AlphaRx is eligible to receive milestone payments of up to $50 million for the successful development and commercialization of GAI-122, as well as royalties on worldwide sales. In addition, Gaia BioPharma has assumed all development costs.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

About Gaia BioPharma

Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics. Gaia BioPharma seeks to address key unmet therapeutic needs by taking established compounds and changing their administration routes to create patent-protected, value-added products.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx Shareholder Update
2. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
3. AlphaRx Signs Cooperative Research and Development Agreement with US Army
4. AlphaRx Provides Corporate and Development Update
5. AlphaRxs Indaflex(TM) Continues its Clinical Development
6. AlphaRx CEO Accumulates More Company Shares
7. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
8. AlphaRx Announces Debt Conversion
9. AlphaRx To Present at 47th Annual ICAAC
10. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
11. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: